Ideas to Action:

Independent research for global prosperity

CGD Policy Blogs

 

Timeline of key events and milestones

Lessons for R&D and Manufacturing Investment for Equitable COVID-19 and Pandemic Response

We conducted a joint review of the portfolio management activities of the committee overseeing COVAX R&D and manufacturing investments, known as RDMIC (R&D and Manufacturing Investment Committee). Our aim was to assess learnings from investments to date and suggest ways to strengthen future global health security preparedness and prevent the inequities observed in the COVID-19 response from repeating.

Supplies being unloaded at a hospital in Donetsk. Photo by Aleksey Filippov / UNICEF

Retooling UNICEF: New Leadership Needs to Couple Humanitarian Imperatives with Systems Reform

UNICEF’s Executive Director, Henrietta Fore, recently announced that she will step down from her position. With a change in leadership imminent, we consider the organization’s dual imperative: to protect children during humanitarian crises - including the current COVID-19 crisis-, and to shift from direct service delivery towards support for systems and policies that will drive sustainable improvements in child well-being today and tomorrow.

A gloved hand holds a COVID-19 vaccine vial in front of a blue background

Dear President Biden and Congress: Time for US to Lead Response to the Growing COVID-19 Global Vaccine Crisis

Today we joined colleagues from CSIS, Duke University, and the COVID Collective in an open letter to the Biden Administration and US Congress with a clear message: to hasten the end of the COVID-19 global pandemic, American leadership is required to ensure universal global access to high-quality and safe vaccines, support rapid vaccine distribution and administration, and build a sustainable global network of vaccine manufacturing capacity. Vaccines offer an exit route out of the pandemic – but only if they reach a critical mass of people in need across continents, socioeconomic strata, and marginalized populations.

A figure of the summary of costs and consequences to consider in COVID-19 vaccine HTA.

Who Gets a COVID-19 Vaccine and Who Pays? The Need for Economic Analysis

In 2020, epidemiological modelling went from relative obscurity to being central in helping governments, and the public, understand COVID-19 as it spread around the world. In 2021, with the emergence of effective COVID-19 vaccines, Health Technology Assessment (HTA) will be critical to making the best possible decisions in bringing the pandemic under control, particularly in low-and middle-income countries (LMICs). In this blog we look at the potential of HTA to inform how much vaccine countries should buy, who should pay, and how vaccines can be most effectively delivered.

A close up of medical supplies, including syringes, at a hospital in Sri Lanka

Expanding Health Product Manufacturing in Africa: Ideas for Development Finance Institutions, Procurers, and Policymakers

In October 2020, the Center for Global Development—in partnership with African Union Development Agency-NEPAD (AUDA-NEPAD), UN Economic Commission for Africa (UNECA), and the African Leaders Malaria Alliance—hosted a high-level roundtable on regional health product manufacturing in Africa. This blog is based on the authors’ reflections of the roundtable.

Pages